Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031691 | 0.81 | HCAR2 (0.48) | CHRNA7HTR3AMAPTCHRNA3 | |
| SCHEMBL13887191 | 0.81 | CHRNA7 (0.46) | CHRNA7HTR3AKMT2ACHRNA3 | |
| SCHEMBL4030339 | 0.81 | GUSB (0.41) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL4029838 | 0.81 | CHRNA7 (0.46) | CHRNA7HTR3AKMT2ACHRNA3 | |
| SCHEMBL13887190 | 0.79 | ALDH1A1 (0.55) | CHRNA7HTR3AMEN1KMT2ARAB9A | |
| SCHEMBL4029530 | 0.79 | ALDH1A1 (0.55) | CHRNA7HTR3AMEN1KMT2ARAB9A | |
| SCHEMBL4027798 | 0.78 | CHRNA7 (0.58) | CHRNA7MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL13887379 | 0.78 | CHRNA7 (0.58) | CHRNA7MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL4027623 | 0.78 | HPGD (0.60) | CHRNA7HTR3ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4032211 | 0.74 | CHRNA7 (0.51) | CHRNA7HTR3AHPGDCHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | claimed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1539764-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016616-A1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1539764-B1 | ARYL-SUBSTITUTED DIAZABICYCLOALKANES AS NICOTINIC ACETYLCHOLINE AGONISTS. | ASTRAZENECA AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885HTR3A 234/4885MEN1 3870/4885 |
| US-20060052368-A1 | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists | CHRNA7, CHRNB1, CHRNA1 | CHRNA7 1/4885HTR3A 202/4885MEN1 2886/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNA7 1/4885HTR3A 214/4885MEN1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.